Biogen Idec, Orphan Biovitrum partner for hemophilia B drug trial

Biogen Idec is collaborating with Orphan Biovitrum on a clinical trial to evaluate the safety and efficacy of a recombinant Factor IX Fc fusion protein in preventing bleeding in hemophilia B patients. Biogen Idec also received FDA approval to market Ampyra, a multiple sclerosis drug it owns with Acorda Therapeutics.

View Full Article in:

Mass High Tech (Boston) · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC